

## Corporate News

November 23, 2015

### MagForce USA Installs the First Clinical NanoActivator® in the USA

**Berlin, Germany, and Nevada, USA, November 23, 2015** - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today that MagForce USA, Inc., MagForce AG's US subsidiary, has successfully installed the first clinical NanoActivator® in the USA. This NanoActivator® is similar in design to the five NanoActivator® devices operating at University Hospitals in Germany applying NanoTherm™ Therapy for the treatment of Brain Tumors. However, the USA NanoActivator® has been modified to apply NanoTherm™ Therapy for the treatment of Prostate Cancer in addition to the treatment of Brain Tumors.

The USA NanoActivator® is located in Seattle, Washington, near the University of Washington Medical Center, and will be utilized in the Focal Thermal Ablation Registration Study for Prostate Cancer for which the Company has filed an Investigational Device Exemption (IDE) with The US Food and Drug Administration (FDA) in May 2015.

#### About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: [www.magforce.com](http://www.magforce.com).

Get to know our Technology: [video \(You Tube\)](#)

Stay informed and subscribe to our [mailing list](#).

#### Corporate News

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • [www.magforce.com](http://www.magforce.com)

For further information:

Anne Hennecke  
MC Services AG

[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)

**T** +49 211 529252 22

**F** +49 211 529252 29

**M** +49 151 12 555 759

## Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

### Corporate News

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • [www.magforce.com](http://www.magforce.com)

For further information:

Anne Hennecke  
MC Services AG

[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)

**T** +49 211 529252 22

**F** +49 211 529252 29

**M** +49 151 12 555 759